Key result
Transcatheter aortic valve-in-valve procedures using the 23 mm Sapien XT valve provide acceptable trans-valvular gradients in 23 mm and 25 mm degenerated bioprostheses with low complication rates.
Why the study?
Does transcatheter aortic valve-in-valve procedure improve procedural success and reduce complications in high-risk patients with degenerated aortic bioprostheses?
Does transcatheter aortic valve-in-valve procedure improve procedural success and reduce complications in high-risk patients with degenerated aortic bioprostheses?
Transcatheter aortic valve-in-valve procedures are a safe and effective, less invasive alternative to redo open heart surgery for high-risk patients with degenerated bioprostheses.
No takes yet. Share an insight, caveat, or question.
Supports targeted 23 mm Sapien XT valve-in-valve use in small bioprostheses; leaves open durability and broader applicability questions.
Enrico Ferrari (2012) conducted a review in Degenerated aortic bioprostheses. Transcatheter aortic valve-in-valve (VinV) implantation was evaluated. Transcatheter aortic valve-in-valve procedures using the 23 mm Sapien XT valve provide acceptable trans-valvular gradients in 23 mm and 25 mm degenerated bioprostheses with low complication rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: